Potential Utility of Sodium Selenate as an Adjunct to Metformin in Treating Type II Diabetes Mellitus in Rats: A Perspective on Protein Tyrosine Phosphatase

Table 1

Effect of daily administration of metformin (250 mg/kg; p.o.) [DIR + Met], sodium selenate (1.89 mg/kg; i.p.) [DIR + Sel], and metformin (250 mg/kg; p.o.) plus sodium selenate (5 mg/kg; i.p.) [DIR + Met + Sel] on body weight and serum content of glucose, insulin, and HOMA-IR index using DIR rats.

Groups	Parameter
	Body weight (g)	Serum glucose (mg/dL)	Serum insulin (𝜇IU/mL)	HOMA-IR index*
Control	326.575 ± 7.77	91.493 ± 2.431	7.975 ± 0.491	1.805 ± 0.127
DIR	226 ± 12.202^c	341.948 ± 28.385^c	8.887 ± 0.216^a	7.511 ± 0.699^c
DIR + Met	289.5 ± 6.214^bf	127.466 ± 1.666^af	11.025 ± 0.220^cf	3.473 ± 0.102^cf
DIR + Sel	207.437 ± 10.821^c	147.779 ± 11.384^bf	15.162 ± 0.128^cf	5.532 ± 0.431^cf
DIR + Met + Sel	208.312 ± 2.864^ci	124.466 ± 3.556^af	12.365 ± 0.226^cflh	3.799 ± 0.126^cfl

Values represent the mean of 8 rats ± SEM (one-way ANOVA followed by LSD test).
^a𝑃<0.05, ^b𝑃<0.01, and ^c𝑃<0.001 compared to the control group. ^f𝑃<0.001 compared to DIR group. ^h𝑃<0.01, ⁱ𝑃<0.001 compared to DIR + Met group. ^l𝑃<0.001 compared to DIR + Sel group.
*HOMA-IR = Fasting serum glucose (mmol/L) × Fasting serum insulin (mIU/L)/22.5.